Lunai Bioworks Inc.
$0.34
▼
-9.47%
2026-04-21 07:55:01
www.lunaibioworks.com
NCM: LNAI
Explore Lunai Bioworks Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$12.33 M
Current Price
$0.34
52W High / Low
$5.5 / $0.15
Stock P/E
—
Book Value
$-0.56
Dividend Yield
—
ROCE
88.63%
ROE
-3.66%
Face Value
—
EPS
$-7.56
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
29
Beta
0.49
Debt / Equity
-0.48
Current Ratio
0.03
Quick Ratio
0.04
Forward P/E
—
Price / Sales
—
Enterprise Value
$11.23 M
EV / EBITDA
-0.9
EV / Revenue
—
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
Cons
- Return on equity is on the weaker side.
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | VivoSim Labs, Inc. | $1.54 | — | $4.02 M | — | -115.61% | -51.07% | $5.3 / $1.25 | $1.7 |
| 2. | Spyre Therapeutics, Inc. | $73.39 | — | $5.76 B | — | -30.53% | -25.17% | $75 / $12.25 | $7.16 |
| 3. | Apellis Pharmaceuticals, Inc. | $40.94 | 233.76 | $5.23 B | — | 7.37% | 7.48% | $40.95 / $16.1 | $2.92 |
| 4. | Ocular Therapeutix, Inc. | $9.52 | — | $2.09 B | — | -35.66% | -54.85% | $16.44 / $6.23 | $3.03 |
| 5. | RenovoRx, Inc. | $1 | — | $45.05 M | — | -176.68% | -2.26% | $1.45 / $0.7 | $0.15 |
| 6. | Climb Bio, Inc. | $8.97 | — | $437.55 M | — | -42.23% | -32.15% | $9.4 / $1.13 | $3.36 |
| 7. | Praxis Precision Medicines, Inc. | $340.84 | — | $9.47 B | — | -37.15% | -45.83% | $356 / $28.79 | $34.85 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -1.82 M | -2.48 M | -4.11 M | -4.16 M | -4.55 M | — |
| Net Profit | -1.8 M | 2.82 M | -126.73 M | 0.19 M | -7.25 M | — |
| EPS in Rs | -0.07 | 0.12 | -5.24 | 0.01 | -0.3 | -2.76 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -18.55 M | -27.39 M | -19.6 M | -22.83 M |
| Net Profit | -178.01 M | -88.43 M | -39.68 M | -113.43 M |
| EPS in Rs | -7.36 | -3.66 | -1.64 | -4.69 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 8.23 M | 163.13 M | 58.3 M | 84.63 M |
| Total Liabilities | 29.58 M | 31.15 M | 11.8 M | 12.01 M |
| Equity | -21.35 M | 131.98 M | 46.5 M | 72.62 M |
| Current Assets | 1.05 M | 2 M | 2.57 M | 9.57 M |
| Current Liabilities | 29.16 M | 30.31 M | 11.02 M | 6.45 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -7.87 M | -10.97 M | -11.77 M | -15.73 M |
| Investing CF | -0.5 M | -1.26 M | -0.03 M | -0.01 M |
| Financing CF | 8.38 M | 10.52 M | 4.52 M | 4.25 M |
| Free CF | -7.87 M | -11.04 M | -11.8 M | -15.74 M |
| Capex | — | -0.07 M | -0.03 M | -0.01 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -122.82% | 65.02% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-09-30 | 1:0.1 |